Trial Profile
An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2014
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary) ; Aminolevulinic acid
- Indications Actinic keratosis; Skin cancer
- Focus Therapeutic Use
- 30 Sep 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 28 Sep 2010 New trial record